Terumo (OTCMKTS:TRUMY – Get Free Report) and Stagezero Life Sciences (OTCMKTS:SZLSF – Get Free Report) are both healthcare companies, but which is the superior stock? Comparatively, Stagezero Life Sciences has a beta of -4.01, meaning that its share price is 501% less volatile than the S&P 500. Get Terumo alerts:Analyst RecommendationsThis is a breakdown of current ratings and price targets for Terumo and Stagezero Life Sciences, as provided by MarketBeat.com. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terumo 0 1 0 1 3.00 Stagezero Life Sciences 0 0 0 0 0.00ProfitabilityNet Margins Return on Equity Return on Assets Terumo 12.09% 9.17% 6.57% Stagezero Life Sciences N/A N/A N/AEarnings and ValuationThis table compares Terumo and Stagezero Life Sciences’ net margins, return on equity and return on assets. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Terumo $7.52 billion 3.11 $897.03 million $0.61 25.98 Stagezero Life Sciences N/A N/A N/A ($0.01) -0.10Terumo has higher revenue and earnings than Stagezero Life Sciences.